Submission of Audited Financial results for the quarter and financial year ended 31.03.2025
Awaiting price reaction for this filing.
MPS Pharmaa Limited (formerly Advik Laboratories) reported zero revenue from operations for FY25, with total income falling to Rs 4.77 lacs from Rs 9.37 lacs in FY24. The company posted a net loss of Rs 89.79 lacs (vs Rs 83.10 lacs loss in FY24), with EPS of Rs (0.47). Drug manufacturing operations remain suspended pending renewal of licences with the FDA Panchkula, and capital work-in-progress of Rs 2.91 crore is stalled. The statutory auditor issued a qualified opinion, flagging lost share certificates for Rs 53.80 lac investments and the stalled capital work, both recurring qualifications since 2017-18, plus an emphasis of matter on nil operating revenue. The company also has unpaid BSE listing fees for four years and shares trade on a trade-for-trade basis.
The stock remains a high-risk, distressed micro-cap with no operating revenue, recurring losses, negative reserves of Rs 1,803 lacs, and a debt-to-equity ratio above 6x. Shareholders face continued uncertainty around business restart, and the qualified audit opinion and unpaid listing fees add governance concerns.